AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-related proteins. Our mission is to develop new class of drugs BIGPRO® (Bi-functional liGand induced PROteolysis) under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
We focus on novel therapies for cancer, neurodegeneration, and aging diseases. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat diseases and diseases plagued by drug resistance.
Company Details
- Employees
- 16
- Founded
- -
- Address
- Taipei, Tw
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- anhornmed.com
- HQ
- Taipei
Anhorn Medicines Questions
Anhorn Medicines's website is anhornmed.com
Anhorn Medicines's LinkedIn profile is https://tw.linkedin.com/company/anhorn-medicines
Anhorn Medicines has
16 employees.
View email and phone details for 16
employees at Anhorn Medicines.
Anhorn Medicines's industry is
Biotechnology Research
Anhorn Medicines's categories are Biotechnology Research
Anhorn Medicines's founding year is 2020
